{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
nonoxynol-9
to a specific field?
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Zoniporide hydrochloride is a novel, potent and selective NHE-1 inhibitor (IC50 = 14 nM). Reduces infarct size in the isolated heart (EC50 = 0.25 nM). Attenuates post-ischemic cardiac contractile dysfunction and ischemia-reperfusion-induced ventricular fibrillation in vivo. Zoniporide hydrochloride represents a novel class of potent and selective human NHE-1 inhibitors with potential utility for providing cardioprotection in a clinical setting.
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Zoniporide hydrochloride is a novel, potent and selective NHE-1 inhibitor (IC50 = 14 nM). Reduces infarct size in the isolated heart (EC50 = 0.25 nM). Attenuates post-ischemic cardiac contractile dysfunction and ischemia-reperfusion-induced ventricular fibrillation in vivo. Zoniporide hydrochloride represents a novel class of potent and selective human NHE-1 inhibitors with potential utility for providing cardioprotection in a clinical setting.
Status:
Investigational
Source:
NCT01381562: Phase 2 Interventional Terminated Infections, Intestinal
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Epetraborole (AN3365 or GSK2251052) is a novel boron-containing antibiotic that inhibits bacterial leucyl tRNA synthetase. It is active against Gram-negative bacteria, including Enterobacteriaceae bearing NDM-1 and KPC carbapenemases, as well as P. aeruginosa. Epetraborole was under development for the treatment of Gram-negative bacterial infections.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Trospectomycin is an aminocyclitol antibiotic similar in structure to spectinomycin. The drug was originally developed by Pharmacia & Upjohn. It is a 6'-propyl analogue of spectinomycin, and lacks the aminosugars in glycosidic linkage which are thought to be responsible for the ototoxicity and nephrotoxicity associated with the aminoglycosides. The mechanism of action of trospectomycin is
similar to that of its parent compound, spectinomycin: it binds to the bacterial 30S
ribosome and inhibits protein synthesis. The transport mechanism for its delivery to its
target site does not appear to be oxygen dependent, and this explains the in-vitro
activity of trospectomycin against anaerobic organisms. Trospectomycin has activity
against a broad spectrum of pathogenic organisms including Streptococcus, Haemophilus, Gardnerella, Neisseria, Peptococcus, Peptostreptococcus, Bacteroides, Mobiluncus,
Chlamydia, Mycoplasma and Ureaplasma spp. Results of in-vivo testing suggest potential utility in a variety of clinical conditions including non-gonococcal urethritis,
chlamydial cervicitis, gonorrhoea, pelvic inflammatory disease, pneumonia, anaerobic
infections and meningitis. Trospectomycin progressed to late stage clinical trials for treatment of pelvic inflammatory disease (chlamydia) before being abandoned for commercial reasons as the third generation cephalosporins and second generation macrolides in development and use were judged superior at the time.
Status:
Investigational
Source:
INN:tetroquinone [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Tetroquinone (Tetrahydroxy-1,4-benzoquinone, tetrahydroxy-p-benzoquinone, tetrahydroxybenzoquinone) is cyclohexadiene derivative with four hydroxyl groups and two ketone groups in opposite (para) positions, with potent prooxidant activity. The exposure of exponentially growing cultures to Tetroquinone, in the presence of Ca2+, caused a dose-dependent inhibition of cell growth and DNA synthesis. The chemical reactivity of Tetroquinone is strongly similar to those of physiological polyphenols, such as catechols and catecholamines. Despite their physiological and pharmacological roles, these compounds may, in addition, present toxicological properties due to their ability to autoxidize generating ROS and quinones Similar to catechols, the OH-substituents confer to Tetroquinone the ability to autoxidize readily in neutral aqueous solutions generating intermediate superoxide anion radicals, semiquinone radicals, and the corresponding quinone. The compound can be synthesized from glyoxal or from myo-inositol (phytic acid), a natural compound widely present in plants.
Status:
Investigational
Source:
USAN:INDIUM CHLORIDES IN 113M [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Indium Chloride In-113 is a salt of the only stable Indium isotope with applications in organic synthesis as a Lewis acid. Indium Chloride is the most available soluble derivative of indium with high reproductive toxicity. In in vitro models, Indium Chloride inhibits cell viability by elevating intracellular ROS and inducing apoptosis. In animal models Indium chloride exposure cause the accumulation of indium in blood and lung, bone marrow micronucleus rate increased, the occurrence of oxidative damage and pathological changes. Besides that, the indium chloride exposed showed significant toxicity to sperm function, as well as an increased percentage of sperm morphological abnormality and chromatin DNA damage.
Status:
Investigational
Source:
NCT01678755: Phase 2 Interventional Completed Schizophrenia
(2012)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
NCT04154956: Phase 3 Interventional Active, not recruiting Non-small Cell Lung Cancer Metastatic
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
USAN:SULFANILATE ZINC [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Sodium sulfanilate is a salt of sulphanilic acid and has been used to monitor the degree of renal dysfunction in dogs.
Status:
Investigational
Source:
NCT01514461: Phase 3 Interventional Completed Familial Chylomicronemia Syndrome (FCS)
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
LCQ908 (Pradigastat) is a diacylglycerol acyltransferase-1 (DGAT-1) inhibitor. DGAT-1 is one of the two DGAT enzymes that catalyse the formation of triglycerides from diacylglycerol and acyl- coenzyme A. DGAT-1 catalyses the final committed step in processing dietary fatty acids into triglycerides carried on chylomicrons for transport around the body. Pradigastat may decrease the level of triglycerides in the blood and is intended for the first line treatment of FCS. It is administered orally at 10-40mg daily in addition to a low fat diet. Pradigastat is also in phase II clinical trials for type 2 diabetes and severe hypertriglyceridaemia (familial hyperchylomicronaemia phenotypes I and V). Pradigastat is a designated orphan drug in the EU. In a phase III clinical trial.
